The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
 
Yutaka Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; MSD Oncology; Nippon Kayaku; Pfizer; Taiho Pharmaceutical; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japanese Breast Cancer Society
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Masato Takahashi
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Pfizer
Research Funding - Eisai (Inst); Nippon Kayaku (Inst)
 
Tetsuhiro Yoshinami
Consulting or Advisory Role - Eisai
Speakers' Bureau - AstraZeneca/Hong Kong; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Kyowa Kirin; Lilly Japan; MSD; Novartis; Pfizer
Research Funding - Lilly Japan
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
Research Funding - Lilly Japan (Inst)
 
Tatsuya Toyama
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takashi Yamanaka
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca/Hong Kong; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly Japan; Nippon Kayaku; Taiho Pharmaceutical
 
Koichiro Tsugawa
Speakers' Bureau - Pfizer
Research Funding - Daiichi Sankyo Pharmaceutical
 
Yoshie Hasegawa
No Relationships to Disclose
 
Kenji Tamura
No Relationships to Disclose
 
Hiroshi Tada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Kyowa Kirin International; Lilly Japan; MSD; Novartis; Pfizer; Takeda
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
 
Naruto Taira
Speakers' Bureau - Eisai; Pfizer
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; MSD; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Devicor Medical Products; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Nippon Kayaku; Novartis; Pfizer; Shimadzu; Sysmex; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Athenex; Bertis; BMS; Daiichi Sankyo; Kansai Medical; Lilly; Terumo
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; GL Sciences; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Lilly (Inst); Lux Biosciences; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanwa Shurui; Shimadzu; Shionogi; Taiho Pharmaceutical; Yakult Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Other Relationship - Asian Journal of Surgery; Asian Journal of Surgery; Breast Cancer research and Treatment; British Journal of Cancer; Cancer Science; Japan Breast Cancer Research Group; Japanese Breast Cancer Society; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research; Scientific Reports
 
Shinji Ohno
Speakers' Bureau - AstraZeneca; AstraZeneca; Chugai/Roche; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin International; Lilly Japan; Lilly Japan; MSD; Nihonkayaku; Nihonkayaku; Pfizer; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai (Inst); Eisai (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group; Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa-Kirin; Lilly Japan; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)